Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 71335-1338

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 71335-1338). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 01)

This is a table indicating drug interactions and recommendations for use with venlafaxine in CYP2D6 EM's and PM's. Some drugs like diazepam and cimetidine need caution during concomitant use while others like ketoconazole and indinavir require monitoring of blood pressure. The recommended adjustments range from avoiding concomitant use to no dose adjustment. The clinical significance of some interactions is unknown. The table also shows PK fold change and 90% C for Cmax and AUC.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 02)

This is a list of drugs that may interact with each other. The list includes drugs such as Diazepam, Alprazolam, Indinavir, Metoprolol, Risperidone, Imipramine, Haloperidol, Caffeine, and Lithium. There are also recommendations for certain analytes such as PKFold Change and 90% C Recommendation for each drug. The text includes information on different drug interactions, such as whether concomitant use should be avoided or if there is no need for a dose adjustment. There is also a section detailing changes relative to the reference value.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 03)

This document appears to be a report on the effects of various factors on the PK of analytes, particularly Venlafaxine. The factors include age, gender, hepatic and renal impairment, and a genetic polymorphism (CYP2D8). The report recommends adjusting the dose of Venlafaxine for certain populations based on fold change and 90% CI. However, the document contains many errors and typos in the text making it difficult to interpret.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 04)

The text "eHCI" and "H4C0 C" are not readable. The readable part of the text is "venlafaxine hydrochloride", which is a medication used to treat depression, anxiety, and panic attacks. It belongs to the class of drugs known as serotonin-norepinephrine reuptake inhibitors (SNRIs). It works by increasing the levels of serotonin and norepinephrine in the brain, which helps improve mood and reduce feelings of anxiety and depression.*

FDA Label Image

Label (Lbl713351338)

This appears to be a label of Venlafaxine HCL, a prescription drug used to treat major depressive disorder, anxiety disorders, and panic disorder. The label shows the brand name, the dosage and type of the capsule, possible side effects, storage instructions, manufacturer's details, and the expiration date. The National Drug Code (NDC) is also displayed which is used to identify drugs in the market.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.